Blood Transfusion Diagnostics Market to Witness Significant Growth by 2032

The blood transfusion diagnostics market (輸血診断市場) is expected to witness a substantial growth trajectory, with a projected CAGR of 7% from USD 4.73 billion in 2022 to USD 8.7 billion by 2032. This growth is fueled by increasing demand and economic expansion. Blood transfusion diagnostics involve conducting tests on blood and its components prior to transfusion to patients. The market is being propelled by the rising prevalence of blood-related ailments like hemophilia, cancer, thrombocytopenia, and chronic kidney disease (CKD), which have led to an increase in the demand for blood products and total blood transfusion. Leading companies are adopting innovative molecular platforms, accelerating the shift from manual tests and equipment to semi-automated and fully automated devices. The introduction of such advanced automated systems has facilitated the implementation of blood transfusion diagnostics and is expected to drive market expansion in the forecast period.

Download a Free Sample Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=4720

Key Takeaways from the Market Study:

Asia-Pacific is expected to witness the fastest growth, with a CAGR of 7.0%
The North American market is anticipated to grow at a favorable CAGR of 6.4%
The blood grouping segment is projected to expand at a CAGR of 5.8% during the forecast period.
China's National Health Commission reported 15.53 million blood donations in 2020.
The European market is forecasted to grow at a favorable CAGR of 6.6%
North America is expected to maintain its position as the global leader in blood transfusion diagnostics. Factors such as a high proportion of voluntary blood donors and the integration of blood transfusion policies for safety and communicable disease testing are crucial for growth. Germany and the United Kingdom are significant contributors to the European blood transfusion diagnostics market, with advancements in surgeries and transplantation methods driving industry progress in these countries.

Market Dynamics:

The market is primarily driven by the growing number of surgeries and trauma cases requiring blood transfusions, along with the rising prevalence of chronic diseases such as cancer and blood disorders. Moreover, the implementation of stringent regulations and standards for blood screening and transfusion safety is also propelling market growth. However, factors such as high costs associated with blood transfusion diagnostics and the risk of transfusion-transmitted infections are hindering market growth to some extent.

Market Future Outlook:

The Blood Transfusion Diagnostics Market (수혈 진단 시장) is expected to witness robust growth in the coming years, driven by the increasing adoption of automated blood screening techniques, rising awareness about transfusion-transmitted infections, and the growing demand for blood and blood products. Additionally, technological advancements in blood typing and cross-matching procedures are expected to further fuel market growth.

Key Players:

Grifols S.A.
Bio-Rad Laboratories, Inc.
Immucor, Inc.
CSL Ltd.
Abbott Laboratories
F. Hoffmann-La Roche Ltd
QUOTIENT
Merck KGaA
DiaSorin S.p.A.

Competitive Landscape:

Key players in the blood transfusion diagnostics market are focusing on integrating technological advancements into their testing procedures. One such advancement is plasma fractionation.

In October 2019, Ortho Clinical Diagnostics received FDA approval for the use of Ortho Sera on its VISION analyzer. This approval marked a significant step in enhancing their testing capabilities.

EryPharm entered the market in April 2021 with an innovative technology that enables the production of red blood cells in large quantities, contributing to the development of new and improved blood transfusion sources.

In March 2021, F. Hoffmann-La Roche Ltd and Bio-Rad Laboratories, Inc. signed a global partnership agreement. This partnership aims to provide customers with access to Bio-Rad's line of InteliQ products and Unity QC data management solutions, further enhancing the quality of blood transfusion diagnostics.

Get Customization on this Report for Specific Research Solutions - https://www.factmr.com/connectus/sample?flag=RC&rep_id=4720

Key Segments Profiled in the Blood Transfusion Diagnostic (Markt für Bluttransfusionsdiagnostik) Industry Survey

By Product Type :

Instruments

Kits & Reagents

By Application :

Blood Grouping

Disease Screening

Molecular Disease Screening

Serological Disease Screening

By End User :

Hospitals

Diagnostic Laboratories

Blood Banks

Plasma Fractionation Companies

Others

By Region :

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.